Elevance Health (ELV)
Coverage summary
Aardvark Labs Capital Research has covered Elevance Health (ELV) since July 18, 2025. The company is in the Healthcare sector. This page lists 6 reports: 6 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published October 25, 2026. The current rating is Hold, unchanged since the Q2 2026 Earnings Recap of July 17, 2026. The rating has changed twice since coverage began.
Translations: 5 in Chinese.
Rating history
All ELV reports
Recap: Q3 2026
Medicaid Turns and the Baseline Rises $0.75, but Investment Marks Supply 81% of the Beat and the Price Already Reflects the Turn: Maintain Hold
Recap: Q2 2026
A Beat Built Below the Line: Compressing Margins and a Stalled Medicaid Trough Sink the Stock 8.5% — Downgrade to Hold
Recap: Q1 2026
Maintaining Outperform: A Nonrecurring-Heavy Beat-and-Raise — But the Recovery Got Confirmed AND De-Risked, With the Medicaid Trough Holding and the 2027 MA Rate Firming, Against a Contained $935M CMS Overhang
Recap: Q4 2025
Upgrading to Outperform: The Trough Is Finally a Number — $25.50 for 2026, a −1.75% Medicaid Bottom, and an Explicit ≥12% Snap-Back in 2027 Off a Washed-Out ~13x Base
Recap: Q3 2025
Maintaining Hold: The Reset Held and the Third Cut Didn't Come — But a $1-of-Below-the-Line "Beat" and a 2026 Management Calls "the Trough" Mean the Recovery Still Can't Be Underwritten
Recap: Q2 2025
Initiating at Hold: A Second Straight In-Year Cut Resets FY25 to ~$30, and Management Won't Touch 2026 — Visibility Is Too Poor to Catch a Knife Down 34% in a Year